Mast cell activation disease: A concise practical guide for diagnostic workup and therapeutic options

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Molderings, Gerhard J ^a   Brettner, Stefan ^b   Homann, Jürgen ^c   Afrin, Lawrence B ^d  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Kreiskrankenhaus Waldbröl ^*  (Germany)

^c Evangelische Kliniken Bonn   (Germany)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHETAMINE; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLESTYRAMINE; CROMOGLYCATE DISODIUM; DIMENHYDRINATE; DIPYRONE; FLUPIRTINE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; IVABRADINE; KETOTIFEN; METOCLOPRAMIDE; MONTELUKAST; NYSTATIN; OXAZEPAM; PARACETAMOL; PENTOSAN POLYSULFATE; PROTON PUMP INHIBITOR; SCOPOLAMINE BUTYL BROMIDE; THIOCTIC ACID; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; VITAMIN D; ANTIHISTAMINIC AGENT;

ABDOMINAL PAIN; AMYLOIDOSIS; ANGIONEUROTIC EDEMA; ANXIETY; ARTHRITIS; ASTHENIA; ASTHMA; BLOATING; BONE PAIN; CARCINOID; CELIAC DISEASE; CELL ACTIVATION; CHOLELITHIASIS; COLIC; CONJUNCTIVITIS; CONSTIPATION; COUGHING; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DYSPNEA; ENDOCRINE TUMOR; ENTERITIS; EOSINOPHILIC GASTROENTERITIS; FATIGUE; FEVER; GASTRITIS; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HEPATITIS; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPEREOSINOPHILIC SYNDROME; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; INSOMNIA; INTERSTITIAL CYSTITIS; INTESTINE LYMPHOMA; INTESTINE OBSTRUCTION; LACTOSE INTOLERANCE; MALABSORPTION; MAST CELL; MAST CELL ACTIVATION DISEASE; MAST CELL DEGRANULATION; MAST CELL LEUKEMIA; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NONCARDIAC CHEST PAIN; ORGANIC BRAIN SYNDROME; OSTEOPENIA; OSTEOPOROSIS; PANCREAS TUMOR; PARASITOSIS; PARESTHESIA; PHEOCHROMOCYTOMA; POLYNEUROPATHY; PORPHYRIA; PRACTICE GUIDELINE; REVIEW; RHINITIS; SINUSITIS; SPLENOMEGALY; SYNCOPE; SYSTEMIC MASTOCYTOSIS; TACHYCARDIA; TELANGIECTASIA; THYROID DISEASE; TINNITUS; URTICARIA; URTICARIA PIGMENTOSA; VERTIGO; VOLVULUS; ANIMAL; DRUG EFFECT; MASTOCYTOSIS; PATHOLOGY;

ANIMALS; HISTAMINE ANTAGONISTS; HUMANS; MAST CELLS; MASTOCYTOSIS;

EID: 79953115973     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-10     Document Type: Review

References (52)

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25:603-625. (Pubitemid 32506768)
2. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453. (Pubitemid 46817344)
3. Homann J, Kolck UW, Ehnes A, Frieling T, Raithel M, Molderings GJ: Systemic mastocytosis - definition of an internal disease. Med Klin (Munich) 2010, 105:544-553.
4. Akin C, Valent P, Metcalfe DD: Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126:1099-1104.
5. Hamilton MJ, Castells M, Greenberger NJ: Mast cell activation syndrome - a newly recognized cause of recurrent acute abdominal pain. Gastroenterology 2010, 138(Suppl 1):S89.
6. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, Mateo MB, Alonso Díaz de Durana MD, de la Hoz B, Del Pozo Gil MD, Caballero T, Rosado A, Sánchez Matas I, Teodósio C, Jara-Acevedo M, Mollejo M, García-Montero A, Orfao A, Escribano L: Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010, 125:1269-1278.
7. Molderings GJ, Kolck UW, Scheurlen C, Brüss M, Homann J, von Kügelgen I: Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 2007, 42:1045-1053. (Pubitemid 47301141)
8. Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T: Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010, 62:721-727.
9. Horan RF, Austen KF: Systemic mastocytosis: retrospective review of a decade's clinical experience at the brigham and the women's hospital. Invest Dermatol 1991, 96:5S-14S.
10. Castells M: Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006, 26:465-485.
11. Hermine O, Lortholary O, Leventhal PS, Catteau A, Soppelsa F, Baude C, Cohen-Akenine A, Palmérini F, Hanssens K, Yang Y, Sobol H, Fraytag S, Ghez D, Suarez F, Barete S, Casassus P, Sans B, Arock M, Kinet JP, Dubreuil P, Moussy A: Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS ONE 2008, 3:e2266.
12. Alfter K, von Kügelgen I, Haenisch B, Frieling T, Hülsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ: New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int 2009, 29:181-186.
13. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J, Jara-Acevedo M, Teodósio C, García-Cosío M, Bellas C, Orfao A: Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009, 124:514-521.
14. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A: Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84:790-794.
15. Lundequist A, Pejler G: Biological implications of preformed mast cell mediators. Cell Mol Life Sci 2011, 68:965-675.
16. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD: Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007, 110:2331-2333.
17. Gonzalez de Olano D, de la Hoz Caballer B, Nunez Lopez R, Sanchez Munoz L, Cuevas Agustin M, Dieguez MC, Alvarez Twose I, Castells MC, Escribano Mora L: Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007, 37:1547-1555. (Pubitemid 47460231)
18. Brockow K, Jofer C, Behrendt H, Ring J: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008, 63:226-232.
19. Sant GR, Kempuraj D, Marchand JE, Theoharides TC: The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007, 69(4 Suppl):34-40.
20. Enestrom S, Bengtsson A, Frodin T: Dermal IgG deposits and increase of mast cells in patients with fibromyalgia - relevant findings or epiphenomena? Scand J Rheumatol 1997, 26:308-313.
21. Lucas HJ, Brauch CM, Settas L, Theoharides TC: Fibromyalgia - new concepts of pathogenesis and treatment. Int J Immunopathol Pharmacol 2006, 19:5-9.
22. Kolck UW: Investigations on the pathogenesis of the systemic mast cell activation syndrome and its impact on heart function. Bonn, University, medical thesis 2009 [http://hss.ulb.uni-bonn.de/2009/1906/1906.htm], URN: nbn:de:hbz:5N-19064.
23. Nickel JC, Tripp DA, Pontari MA, Moldwin RM, Mayer R, Carr LK, Doggweiler R, Yang CC, Whitcomb D, Mishra N, Nordling J: Phenotypic associations between interstitial cystitis/painfil bladder syndrome and irritable bowel syndrtome, fibromyalgia, chronis fatigue syndrome: a case control study. J Urology 2009, 181(Suppl):19.
24. Frieling T, Meis K, Kolck UW, Homann J, Hülsdonk A, Haars U, Hertfelder H-J, Oldenburg J, Seidel H, Molderings GJ: Evidence for mast cell activation in patients with therapy-resistant irritable bowel syndrome. Z Gastroenterol 2011, 49:191-194.
25. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L: REMA: Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007, 138:12-30. (Pubitemid 46889785)
26. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, Hadj-Rabia S, Nasca L, Georgin-Lavialle S, Cohen-Akenine A, Launay JM, Barete S, Feger F, Arock M, Catteau B, Sans B, Stalder JF, Skowron F, Thomas L, Lorette G, Plantin P, Bordigoni P, Lortholary O, de Prost Y, Moussy A, Sobol H, Dubreuil P: Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
27. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372. (Pubitemid 44497521)
28. Lawley W, Hird H, Mallinder P, McKenna S, Hargadon B, Murray A, Bradding P: Detection of an activating c-kit mutation by real-time PCR in patients with anaphylaxis. Mutation Res 2005, 572:1-13. (Pubitemid 40403650)
29. Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, Bilban M, Esterbauer H, Krauth MT, Sperr WR, Longley JB, Kralovics R, Moriggl R, Zappulla J, Liblau RS, Schwarzinger I, Sexl V, Sillaber C, Valent P: Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008, 180:5466-5476.
30. Teodosio C, García-Montero AC, Jara-Acevedo M, Sánchez-Muñoz L, Alvarez-Twose I, Núñez R, Schwartz LB, Walls AF, Escribano L, Orfao A: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunopheno-types. J Allergy Clin Immunol 2010, 125:719-726.
31. Yang Y, Létard S, Borge L: Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010, 116:1114-1123.
32. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE: Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005, 106:2865-2870. (Pubitemid 41510766)
33. Molderings GJ, Kolck U, Scheurlen C, Brüss M, Frieling T, Raithel M, Homann J: Systemic mast cell disease with gastrointestinal symptoms - a diagnostic questionnaire. Dtsch Med Wochenschr 2006, 131:2095-2100. (Pubitemid 44544026)
34. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D: Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007, 217:65-78. (Pubitemid 46718152)
35. Roberts LJ, Oates JA: Biochemical diagnosis of systemic mast cell disorders. J Invest Dermatol 1991, 96(3 Suppl):19S-24S.
36. Butterfield JH, Li C-Y: Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient? Am J Clin Path 2004, 121:264-267. (Pubitemid 38140132)
37. Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J: Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med 2011, 50:1-5.
38. Droogendijk HJ, Kluin-Nelemans HJC, van Doormaal JJ, Oranje AR, van de Loosdrecht AA, van Daele PLA: Imatinib mesylate in the treatment of systemic mastocytosis - A phase II trial. Cancer 2006, 107:345-351. (Pubitemid 44036564)
39. Gotlib J, George TI, Corless C, Linder A, Ruddell A, Akin C, DeAngelo DJ, Kepten I, Lanza C, Heinemann H, Yin O, Gallagher N, Graubert T: The Kit tyrosine kinase inhibitor midostaurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial. Blood 2008, 110:1039A.
40. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, Akin C, Faderl S, Manshouri T, Thomas D, Kantarjian H: Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14:3906-3915.
41. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009, 33:1481-1484.
42. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S: Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymph 2010, 51:269-274.
43. de Olano DG, Twose IA, Esteban López MI, Muñoz LS, Alonso Díaz de Durana MD, Castro AV, Montero AG, González-Mancebo E, González TB, Herrero Gil MD, Fernández-Rivas M, Orfao A, de la Hoz Caballer B, Castells MC, Mora LE: Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008, 121:519-526.
44. Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Körner M, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B: Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009, 124:1047-1054.
45. Bonadonna P, Zanotti R, Müller U: Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10:347-353.
46. Valent P, Sperr WR, Akin C: How I treat patients with advanced systemic mastocytosis. Blood 2010, 116:5812-5817.
47. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A: Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009, 113:5727-5736.
48. Simon J, Lortholary O, Caillat-Vigneron N, Raphael M, Martin A, Briere J, Barete S, Hermine O, Casussus P: Interest of interferon alpha in systemic mastocytosis. The french experience and review of the literature. Pathol Biol 2004, 52:294-299.
49. Butterfield JH: Interferon treatment for hypereosinophilic syndromes ans systemic mastocytosis. Acta haematol 2005, 114:26-40.
50. Afrin LB: Polycythemia from mast cell activation disorder: lessons from incongruence of symptoms vs. test results. Am J Med Sci 2011.
51. Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, Dubreuil P, Arock M, Roux C, Launay JM, Fraitag S, Canioni D, Billemont B, Suarez F, Lanternier F, Lortholary O, Hermine O, Francès C: Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010, 69:1838-1841.
52. Molderings GJ, Solleder G, Kolck UW, Homann J, Schröder D, von Kügelgen I, Vorreuther R: Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics. Urol Res 2009, 37:227-229.